JP2014530003A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530003A5
JP2014530003A5 JP2014531931A JP2014531931A JP2014530003A5 JP 2014530003 A5 JP2014530003 A5 JP 2014530003A5 JP 2014531931 A JP2014531931 A JP 2014531931A JP 2014531931 A JP2014531931 A JP 2014531931A JP 2014530003 A5 JP2014530003 A5 JP 2014530003A5
Authority
JP
Japan
Prior art keywords
domain
influenza virus
glycosylation site
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014531931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530003A (ja
JP6498439B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/056122 external-priority patent/WO2013043729A1/en
Publication of JP2014530003A publication Critical patent/JP2014530003A/ja
Publication of JP2014530003A5 publication Critical patent/JP2014530003A5/ja
Application granted granted Critical
Publication of JP6498439B2 publication Critical patent/JP6498439B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014531931A 2011-09-20 2012-09-19 インフルエンザウイルスワクチン及びその使用 Expired - Fee Related JP6498439B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201161536924P 2011-09-20 2011-09-20
US61/536,924 2011-09-20
US201161565899P 2011-12-01 2011-12-01
US61/565,899 2011-12-01
US201261607526P 2012-03-06 2012-03-06
US61/607,526 2012-03-06
US201261648525P 2012-05-17 2012-05-17
US61/648,525 2012-05-17
US201261670108P 2012-07-10 2012-07-10
US61/670,108 2012-07-10
US201261684481P 2012-08-17 2012-08-17
US61/684,481 2012-08-17
PCT/US2012/056122 WO2013043729A1 (en) 2011-09-20 2012-09-19 Influenza virus vaccines and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018024070A Division JP2018110585A (ja) 2011-09-20 2018-02-14 インフルエンザウイルスワクチン及びその使用

Publications (3)

Publication Number Publication Date
JP2014530003A JP2014530003A (ja) 2014-11-17
JP2014530003A5 true JP2014530003A5 (enExample) 2015-11-12
JP6498439B2 JP6498439B2 (ja) 2019-04-17

Family

ID=47914828

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014531931A Expired - Fee Related JP6498439B2 (ja) 2011-09-20 2012-09-19 インフルエンザウイルスワクチン及びその使用
JP2018024070A Pending JP2018110585A (ja) 2011-09-20 2018-02-14 インフルエンザウイルスワクチン及びその使用
JP2020012913A Pending JP2020096604A (ja) 2011-09-20 2020-01-29 インフルエンザウイルスワクチン及びその使用
JP2022034315A Pending JP2022091775A (ja) 2011-09-20 2022-03-07 インフルエンザウイルスワクチン及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018024070A Pending JP2018110585A (ja) 2011-09-20 2018-02-14 インフルエンザウイルスワクチン及びその使用
JP2020012913A Pending JP2020096604A (ja) 2011-09-20 2020-01-29 インフルエンザウイルスワクチン及びその使用
JP2022034315A Pending JP2022091775A (ja) 2011-09-20 2022-03-07 インフルエンザウイルスワクチン及びその使用

Country Status (17)

Country Link
US (2) US10131695B2 (enExample)
EP (2) EP4241785A3 (enExample)
JP (4) JP6498439B2 (enExample)
KR (1) KR20140068205A (enExample)
CN (3) CN116162175A (enExample)
AR (1) AR090392A1 (enExample)
AU (2) AU2012312529B2 (enExample)
BR (1) BR112014006694A2 (enExample)
CA (1) CA2849434A1 (enExample)
EA (1) EA201490659A1 (enExample)
ES (1) ES2953393T3 (enExample)
HK (1) HK1200102A1 (enExample)
IL (2) IL231547B (enExample)
IN (1) IN2014CN02114A (enExample)
MX (1) MX2014003308A (enExample)
SG (1) SG11201400743VA (enExample)
WO (1) WO2013043729A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
WO2013043729A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
PL3052192T3 (pl) 2013-10-02 2021-04-06 Medimmune, Llc Przeciwciała neutralizujące przeciwko grypie A i ich zastosowania
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
PT3134131T (pt) * 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
EP3149479A2 (en) * 2014-05-30 2017-04-05 Sanofi Pasteur Inc. Expression and conformational analysis of engineered influenza hemagglutinin
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and their uses
CN113563462B (zh) 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
AU2016258929B2 (en) 2015-05-04 2020-10-08 Epivax, Inc. Modified H7 hemagluttinin glycoprotein of the influenza A/Shanghai/2/2013 H7 sequence
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
LT3303384T (lt) 2015-06-01 2021-10-11 Medimmune, Llc Neutralizuojančios surišančios molekulės prieš gripą ir jų naudojimas
WO2016205347A1 (en) * 2015-06-16 2016-12-22 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
RU2769406C2 (ru) * 2016-02-03 2022-03-31 СиДжи ДИСКАВЕРИ, ИНК. Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
JP6868763B2 (ja) * 2016-04-01 2021-05-12 パナソニックＩｐマネジメント株式会社 インフルエンザウィルスに結合する抗体
US20190125859A1 (en) * 2016-06-03 2019-05-02 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US11116832B2 (en) * 2016-06-03 2021-09-14 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides
EP3471767A4 (en) * 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
IL303650B2 (en) 2016-09-02 2025-02-01 Us Health Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
WO2018085488A1 (en) 2016-11-02 2018-05-11 Iowa State University Research Foundation, Inc. Universal mammalian influenza vaccine
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
MX2020010199A (es) * 2018-04-03 2021-01-08 Sanofi Sa Polipeptidos antigenicos del virus sincitial respiratorio.
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
WO2019222674A1 (en) * 2018-05-18 2019-11-21 Chan Zuckerberg Biohub, Inc. Epitope restriction for antibody selection
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020014675A1 (en) * 2018-07-13 2020-01-16 University Of Georgia Research Foundation Methods for generating pan-epitopic immunogens of influenza h3 virus, compositions and methods of use thereof
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN109096376A (zh) * 2018-09-20 2018-12-28 扬州大学 流感病毒ha多肽、klh偶联多肽及多克隆抗体的制备方法
KR102098585B1 (ko) * 2018-11-21 2020-04-08 고려대학교 산학협력단 교차 면역원성을 갖는 h2 아형 인플루엔자 바이러스 및 이를 포함하는 백신
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
WO2020210149A1 (en) * 2019-04-06 2020-10-15 Altimmune Inc Broad and long-lasting influenza vaccine
EP4031558A4 (en) * 2019-09-20 2023-05-31 Academia Sinica CHIMERIC HEMAGGLUTININ PROTEIN AND VACCINE COMPOSITION COMPRISING THEM
CA3158145A1 (en) * 2019-10-15 2021-04-22 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
MX2022014013A (es) 2020-05-08 2023-01-30 Academia Sinica Vacunas quimericas contra la influenza.
CN112111503B (zh) * 2020-08-24 2023-04-07 河北省动物疫病预防控制中心 同时预防禽流感h5和h9亚型的腺病毒载体二价苗及其制备方法
US20240050551A1 (en) * 2021-01-12 2024-02-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Herpes simplex virus type 1 derived influenza vaccine
CN113082187B (zh) * 2021-04-09 2023-06-27 北京红太阳药业有限公司 小柴胡提取物与阿奇霉素联合在治疗病毒性肺炎中的应用
EP4164687A4 (en) 2021-04-12 2024-08-14 Academia Sinica IMPROVED CORONAVIRUS VACCINE
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
WO2025092866A1 (zh) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US5182192A (en) 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
JP3037554B2 (ja) 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
WO1996011279A2 (en) 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
ATE426031T1 (de) 1995-09-14 2009-04-15 Virginia Tech Intell Prop Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
WO1997040177A1 (en) 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
WO1997040161A1 (en) 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medecine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
KR100894670B1 (ko) 1996-07-15 2009-04-22 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포융합 바이러스 백신의 생산
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
CN1232504A (zh) 1996-09-27 1999-10-20 美国氰胺公司 在单链负义病毒目病毒内引起减毒的3'基因组启动子区和聚合酶基因中的突变
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
KR100663319B1 (ko) 1997-04-14 2007-01-02 마이크로메트 에이지 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998053078A1 (en) 1997-05-23 1998-11-26 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
ATE361973T1 (de) 1997-07-11 2007-06-15 Univ Yale Rhabdovirus mit gentechnisch veränderter hülle
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
PT1085904E (pt) 1998-06-12 2013-03-05 Sinai School Medicine Vírus de cadeia negativa atenuados com actividade antagonista do interferão alterada, para utilização como vacinas e produtos farmacêuticos
JP4441595B2 (ja) 1998-06-12 2010-03-31 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー インターフェロン誘導性の遺伝子工学的に作製された弱毒ウイルス
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6551820B1 (en) 1998-12-23 2003-04-22 Boyce Thompson Institute For Plant Research Expression of immunogenic hepatitis B surface antigens in transgenic plants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AU4134000A (en) 1999-04-29 2000-11-17 Syngenta Limited Herbicide resistant plants
DE122008000056I1 (de) 1999-07-14 2009-04-09 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren
DE60036952T2 (de) 1999-09-24 2008-08-07 Glaxosmithkline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
AU2001250856A1 (en) 2000-03-17 2001-10-03 Charles Arntzen Expression of recombinant human acetylcholinesterase in transgenic plants
AU2001259211B2 (en) 2000-04-28 2006-07-13 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
ATE376059T1 (de) * 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
HUE050222T2 (hu) 2002-02-13 2020-11-30 Wisconsin Alumni Res Found Szignál influenzavírus-vektorok pakolására
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
CA2496384C (en) * 2002-08-20 2016-11-01 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP2006521095A (ja) 2003-01-29 2006-09-21 ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 寛容誘導標的特異性抗体の生成
JP4675317B2 (ja) 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4368594B2 (ja) 2003-02-24 2009-11-18 株式会社インシリコサイエンス タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
ZA200508930B (en) 2003-05-05 2007-03-28 Thompson Boyce Inst Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
PL1692265T3 (pl) 2003-11-04 2011-12-30 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
AU2005248377B2 (en) 2004-05-25 2011-03-24 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2006040764A2 (en) 2004-10-13 2006-04-20 Protalix Ltd. System and method for production of antibodies in plant cell culture
JP2008519042A (ja) * 2004-11-03 2008-06-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インフルエンザワクチン接種
EP1851238A4 (en) 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
JP4758148B2 (ja) 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
KR20070000554A (ko) 2005-06-27 2007-01-03 삼성전자주식회사 이종 망에서 복합 서비스를 위한 자원 관리방법
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
AU2006322907B2 (en) 2005-12-06 2012-08-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
KR20080106433A (ko) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
US20070207171A1 (en) 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
US20070262178A1 (en) 2006-05-12 2007-11-15 Ultradent Products, Inc. Syringe delivery tip including an enlarged flocked wing element adjacent a distal delivery end
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US20100049163A1 (en) 2006-06-27 2010-02-25 Addbio Ab Drug delivery device, kit and method for peroperative local pharmacological treatment of bone surfaces
EP2035565A4 (en) 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
AU2007275010B2 (en) 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
EP2066345B1 (en) 2006-09-11 2015-02-25 Novartis AG Making influenza virus vaccines without using eggs
EP2174957B1 (en) 2007-06-15 2016-03-16 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
JP2010533737A (ja) 2007-07-19 2010-10-28 ノババックス，インコーポレイテッド キメラ水痘帯状疱疹ウイルス−ウイルス様粒子
WO2009025770A2 (en) 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
US9421254B2 (en) 2007-09-24 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunostimulatory combinations of TLR ligands and methods of use
FR2921387B1 (fr) 2007-09-26 2012-04-20 Sanofi Pasteur Procede de production du virus de la grippe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
KR20100120157A (ko) 2007-11-27 2010-11-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
CA2708221C (en) 2007-12-06 2017-07-25 Wayne A. Marasco Antibodies against influenza virus and methods of use thereof
WO2009092038A1 (en) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US20100040635A1 (en) 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
US8592557B2 (en) 2008-06-17 2013-11-26 Apogenix Gmbh Multimeric TNF receptor fusion proteins and nucleic acids encoding same
JP5756750B2 (ja) 2008-06-25 2015-07-29 インセルム（インスティチュート ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） フラジェリンに基づく新規の免疫アジュバント化合物及びその使用
EP2294202B1 (en) * 2008-07-08 2015-05-20 Medicago Inc. Soluble recombinant influenza antigens
WO2010036948A2 (en) 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
HRP20180706T1 (hr) 2009-06-24 2018-06-01 Medicago Inc. Kimerna gripa nalik čestici koja sadrži hemaglutinin
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
JP5463107B2 (ja) 2009-09-14 2014-04-09 独立行政法人国立国際医療研究センター 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬
WO2011044152A1 (en) 2009-10-05 2011-04-14 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Protection against pandemic and seasonal strains of influenza
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP2545074A4 (en) 2010-03-08 2014-01-08 Celltrion Inc HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
AU2011282423B2 (en) 2010-07-22 2015-05-14 Schrader, Sabariah Cross-protective pathogen protection, methods and compositions thereof
WO2013043729A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
CN104066446B (zh) 2011-11-28 2017-10-03 扬森疫苗与预防公司 流感病毒疫苗及其用途
US10023629B2 (en) 2012-12-11 2018-07-17 Vib Vzw Anti-influenza antibody
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
RU2015132962A (ru) 2013-01-10 2017-02-14 Новартис Аг Иммуногенные композиции на основе вируса гриппа и их применение
JP6525469B2 (ja) 2013-03-13 2019-06-05 ノバルティス アーゲー インフルエンザｂ型ウイルス再集合
IL241552B2 (en) 2013-03-14 2023-09-01 Contrafect Corp Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP2968523A4 (en) 2013-03-15 2016-07-20 Univ Pennsylvania INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MANUFACTURED THEREOF
PL235555B1 (pl) 2014-06-24 2020-09-07 Inst Biotechnologii I Antybiotykow Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2016205347A1 (en) 2015-06-16 2016-12-22 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US20190125859A1 (en) 2016-06-03 2019-05-02 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof

Similar Documents

Publication Publication Date Title
JP2014530003A5 (enExample)
JP6957580B2 (ja) 新規多価ナノ粒子に基づくワクチン
JP2018110585A5 (enExample)
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP2013526849A5 (enExample)
JP2016199557A5 (enExample)
CA2857087C (en) Influenza virus vaccines and uses thereof
JP2015212284A5 (enExample)
JP2012521786A5 (enExample)
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
JP2008524261A5 (enExample)
JP2014507146A5 (enExample)
JP2018507860A5 (enExample)
JP2016520534A5 (enExample)
CN107847575A (zh) 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物
EP2758072A1 (en) Vaccibodies targeted to cross-presenting dendritic cells
WO2021043869A1 (en) Influenza virus vaccines and uses thereof
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
DE602008005857D1 (de) Neue antimalaria-impfstoffzusammensetzungen und anwendungen davon
WO2013066365A1 (en) Immunologic constructs and methods
JP2015524420A5 (enExample)
RU2007129962A (ru) Универсальная вакцина против вируса гриппа птиц
TR201900695T4 (en) HPV / CYAA-BASED CHEMICAL PROTEINS AND THEIR USE IN INDUCING IMMUNE RESPONSE AGAINST HPV INFECTION AND HPV-INDUCED DISASTER.
JP6983653B2 (ja) ワクチン